Curevo Vaccine

Investor: Eli Lilly and Company

Eli Lilly and Company has acquired Curevo Vaccine, a biotech company developing a next-generation shingles vaccine that incorporates the Access to Advanced Health Institute’s (AAHI) proprietary SLA-SE adjuvant technology. Summary of transaction details: Value: Not Disclosed Sector: Healthcare & Biotech Advisor: Not Disclosed Key Entities: Eli Lilly and Company, Curevo Vaccine, Access to Advanced Health Institute (AAHI) Location: United States Note: This acquisition highlights the growing importance of next-generation adjuvants in vaccine development and is expected to have a significant impact on the healthcare and biotech industry.